Lub luag hauj lwm ntawm Histone Deacetylases nyob rau hauv lub raum kev loj hlob thiab kab mob Part 2

HDACs thiab lub raum carcinoma

HDAC inhibitors tau kawm ntau yam hauv ntau hom mob qog noj ntshav. Lub raum cell carcinoma (RCC) yog mob qog noj ntshav raum ntau tshaj plaws thiab suav txog 2-3 feem pua ntawm cov neeg mob qog noj ntshav hauv Tebchaws Meskas [53]. Chav Kawm I HDACs, tshwj xeeb tshaj yog HDAC1, 2, thiab 3 tau qhia ntau heev hauv RCC, ua rau lawv nthuav lub hom phiaj rau kev kho mob [54]. Cov kev tshawb fawb tsis ntev los no tau pom tias HDAC1 thiab HDAC2 yuav tsum muaj rau kev loj hlob thiab ciaj sia ntawm lub raum mob hlwb [55]. HDAC ua rau txo qis ntawm E-cadherin (lub cell adhesion molecule) thiab platelet-derived growth factor receptor (PDGFR, tus tsav tsheb tseem ceeb ntawm RCC metastasis tsim) [55]. Clear cell renal cell carcinoma (ccRCC) yog hom kab mob khees xaws mis ntau tshaj plaws. ccRCC yog tus cwj pwm los ntawm qhov tsis ua haujlwm ntawm cov qog qog nqaij hlav gene von Hippel Lindau (VHL) [56]. Cov kev tshawb fawb pom tau tias HDAC1 thiab 6 yog qhov qhia tau zoo heev thiab hloov pauv kev cuam tshuam ntawm tes thiab tsiv teb tsaws hauv ccRCC [56]. Tsis ntev los no, peb kuj tau kuaj pom kev ua haujlwm siab dua ntawm HDAC1 thiab HDAC2 hauv Wilms Tumor, cov qog nqaij hlav cancer ntawm lub raum uas tshwm sim los ntawm lub raum tsis paub qab hau (Liu li al., unpublished). Los ntawm kev tsom mus rau ob qho tib si histone thiab non-histone proteins, HDACs ua lub luag haujlwm tseem ceeb hauv kev loj hlob thiab kev loj hlob ntawm cov qog nqaij hlav [57]. HDACi tau ua pov thawj los ua kom muaj txiaj ntsig zoo rau kev loj hlob, apoptosis, thiab kev sib txawv ntawm cov qog nqaij hlav cancer, thiab inhibition ntawm qog angiogenesis [57, 58].

CISTANCHE HERBS FOR KIDNEYS

Cov ntaub ntawv pov thawj tau pom tias HDACi inhibits qog nqaij hlav qog noj ntshav thiab ua rau lub voj voog ntawm tes raug ntes [57, 58]. Kev kho VPA ntawm RCC hlwb ua rau G1 raug ntes los ntawm kev tswj hwm ntawm p21 [59]. Tsis tas li ntawd, LBH589 (panobinostat; Farydak®, Novartis Pharms Corp.) induced G2 / M ntes ntawm RCC hlwb los ntawm depletion ntawm aurora A thiab B thiab downregulation ntawm Survivin [60], uas tau tshwj xeeb kho los ntawm HDAC3 thiab 6 [60] . Aurora A thiab B yog cov kev txuag tau zoo heev serine/threonine kinases uas ua lub luag haujlwm tseem ceeb thaum lub sij hawm mitosis thiab meiosis, tshwj xeeb tshaj yog nyob rau hauv G2-M cell cycle. Survivin yog ib tug tswv cuab ntawm inhibitor ntawm apoptosis (IAP) tsev neeg, uas ua haujlwm rau inhibit apoptosis lossis programmed cell tuag. G2 / M raug ntes kuj tau raug ntxias los ntawm KBH-A145, ib-lactam-based hydroxamic acid derivative uas inhibits HDAC [61]. Hauv tib neeg lub raum qog noj ntshav, KBHA145 upregulates p21 los ntawm inhibiting kev nrhiav neeg ua haujlwm ntawm HDAC1 rau p21 txhawb nqa [61]. Sib sau ua ke, cov kev tshawb pom no qhia tias HDAC inhibitors ua rau lub voj voog raug ntes hauv RCC los ntawm kev cuam tshuam rau lub voj voog ntawm tes, xws li p21, aurora A, thiab aurora B.

Txawm hais tias FDA pom zoo rau kev kho mob ntawm ntau cov qog nqaij hlav, kev siv tshuaj kho ib leeg ntawm HDAC inhibitor (HDACi) tau txwv txoj kev kho tau zoo tiv thaiv cov qog nqaij hlav [62]. Ntau cov kev tshawb fawb tau pom cov txiaj ntsig ntawm kev siv cov HDACis sib xyaw nrog lwm cov kab mob qog noj ntshav rau kev kho RCC [58]. Piv txwv li, VPA ua ke nrog cov tshuaj tsawg-interferon , lossis AEE788 (ib qho receptor tyrosine kinase inhibitor), lossis RAD001 (ib qho inhibitor ntawm mTOR), muaj txiaj ntsig zoo dua hauv inhibiting HDAC kev ua haujlwm thiab cell proliferation hauv RCC hlwb [63]. Cov txiaj ntsig ntawm ib leeg caj npab I / II txoj kev tshawb fawb qhia tau hais tias qhov sib ntxiv ntawm chav kawm 1 HDAC inhibitor entinostat rau high-dose IL-2 kev kho mob hauv cov neeg mob nrog metastatic ccRCC tej zaum yuav muaj txiaj ntsig [64]. Tib pab pawg kuj tau tshaj tawm tias kev sib koom ua ke ntawm chav kawm II HDAC inhibitor vorinostat thiab VEGF blocker bevacizumab kuj tau txais txiaj ntsig zoo nyob rau hauv ib sab caj npab I / II kev sim tshuaj [65].

cistanche kidney FDA

Sib sau ua ke, cov kev tshawb fawb no tau pom zoo tias HADC inhibition, tshwj xeeb tshaj yog thaum ua ke nrog cov kws kho mob ntxiv, tuaj yeem muab txoj hauv kev zoo rau kev kho RCC.

Raws li kev tshawb fawb cuam tshuam,cistancheyog ib txwm suav tshuaj ntsuab uas tau siv rau ntau pua xyoo los kho ntau yam kab mob. Nws tau raug pov thawj scientific kom muaj cov tshuaj tiv thaiv kab mob, tiv thaiv kev laus, thiab antioxidant zog. Cov kev tshawb fawb tau qhia tiascistanchemuaj txiaj ntsig zoo rau cov neeg mob kev txom nyem los ntawmkab mob raum. Cov khoom xyaw nquag ntawm cistanche paub tias txo qhov mob,txhim kho lub raum ua haujlwmthiab restore lub raum puas hlwb. Yog li, kev sib koom ua kecistanchenyob rau hauv txoj kev npaj kho mob raum tuaj yeem muab txiaj ntsig zoo rau cov neeg mob hauv kev tswj hwm lawv tus mob.

Cistanchepab txo qis proteinuria, txo qis BUN thiab creatinine qib, thiab txo qis kev pheej hmoo ntxivraum puas. Ntxiv rau,cistanchekuj tseem pab txo qis cov roj cholesterol thiab triglyceride uas tuaj yeem ua rau muaj kev phom sij rau cov neeg mob uas muaj kab mob raum.

which cistanche is best

Nyem rau ntawm Cistanche Tubulosa Rau Raum Kab Mob

Nug ntxiv:

david.deng@wecistanche.com WhatApp:86 13632399501

Cistanche's antioxidant thiab anti-aging zog pab rautiv thaiv covlub raumlos ntawm oxidation thiab kev puas tsuaj los ntawm dawb radicals. Qhov no txhim kho lub raum noj qab haus huv thiab txo cov kev pheej hmoo ntawm kev tsim teeb meem.Cistanchekuj pab txhawb lub cev tiv thaiv kab mob, uas yog qhov tseem ceeb hauv kev tawm tsam cov kab mob raum thiabtxhawb lub raum noj qab haus huv.

Los ntawm kev sib txuas cov tshuaj suav tshuaj ntsuab thiab cov tshuaj sab hnub poob niaj hnub no, cov neeg txom nyem los ntawm kab mob raum tuaj yeem muaj ntau txoj hauv kev los kho tus mob thiab txhim kho lawv lub neej zoo.Cistancheyuav tsum tau siv los ua ib feem ntawm txoj kev npaj kho mob tab sis tsis yog siv los ua lwm txoj hauv kev kho mob.

Kev xaus thiab kev pom

HDACs, tshwj xeeb tshaj yog hauv chav kawm I HDACs, tau pom tias ua lub luag haujlwm tseem ceeb hauv kev loj hlob ntawm lub raum [4, 23, 27, 9]. Aberrant qhia theem thiab kev ua haujlwm ntawm HDACs muaj feem cuam tshuam nrog pathogenesis thiab kev loj hlob ntawm ntau yam kab mob raum. Ntau HDACi tau pom tias muaj txiaj ntsig zoo hauv kev kho mob raum. Cov ntaub ntawv qhia ntxaws txog kev kho mob ntawm histone deacetylase inhibitors ntawm cov kab mob raum tau muab rau hauv daim ntawv tshuaj xyuas (Chun, 2018). Cov kev tshawb fawb ntxiv yog tsim nyog kom nkag siab zoo dua cov txheej txheem molecular ntawm HDACs hauv lub raum tsim thiab kab mob raum. HDACs thiab HDACi tswj (lossis hloov) cov noob qhia los ntawm kev hloov cov protein acetylation. Tam sim no, qhov profile ntawm HDAC-modulated los yog HDCAi-mediated protein acetylation nyob rau hauv ob lub raum (ntawm physiological lossis pathological mob) tsis paub zoo. Kev soj ntsuam dav dav ntawm cov protein lysine acetylation thoob ntiaj teb hauv kev teb rau HDAC knockout lossis HDAC inhibition siv cov txheej txheem proteomic yuav muab cov kev nkag siab tshiab rau hauv cov txheej txheem tswj hwm ntawm HDACs hauv kev loj hlob raum thiab qhib txoj kev kho tshiab rau kev tiv thaiv thiab kho cov kab mob raum thiab cuam tshuam rau lub raum-kuaj plawv. kab mob. Ntau cov kev tshawb fawb tau ua tiav pom tau hais tias cov nyhuv renoprotective ntawm HDAC inhibitors, txawm li cas los xij, feem ntau ntawm lawv yog pan-HDAC inhibitors. Broad-spectrum HDAC inhibition feem ntau yuav ua rau nephrotoxicity, thiab kev txhim kho ntawm HDAC inhibitors tshwj xeeb yog xav tau los txhim kho cov txiaj ntsig kev kho mob thiab txo cov tshuaj toxicity. Combinatorial therapy los ntawm kev sib txuas HDAC inhibitors nrog cov neeg ua haujlwm ntxiv kuj tseem yuav muaj txiaj ntsig zoo rau kev kho mob. Tsis tas li ntawd, kev nkag siab zoo txog lub luag haujlwm ntawm HDACs thiab HDAC inhibitors tseem yuav yog qhov kev pabcuam zoo rau kev txhim kho cov cuab yeej tshiab los rov ua dua nephrogenesis hauv cov tshuaj kho dua tshiab.

cistanche lost empire

Kev lees paub

Ua tsaug ntau rau Dr. El-Dahr rau kev nyeem ntawv thiab kho cov ntawv sau no. Kev tshawb fawb tau tshaj tawm hauv cov ntawv tshaj tawm no tau txais kev txhawb nqa los ntawm American Heart Association (17SDG33660072), National Institutes of Health pab nyiaj P50 DK096373-03 thiab P30GM103337.

Qhib Access

Kab lus no tau tso cai raws li Creative Commons Attribution 4.0 Daim ntawv tso cai thoob ntiaj teb, uas tso cai siv, sib koom, hloov kho, faib, thiab luam tawm hauv ib qho nruab nrab lossis hom ntawv, tsuav yog koj muab credit rau tus thawj sau ) thiab qhov chaw, muab qhov txuas mus rau Creative Commons daim ntawv tso cai, thiab qhia seb puas tau hloov pauv. Cov duab lossis lwm yam khoom siv thib peb hauv tsab xov xwm no suav nrog hauv tsab xov xwm Creative Commons daim ntawv tso cai tshwj tsis yog qhia lwm yam hauv kab qiv nyiaj rau cov khoom siv. Yog tias cov ntaub ntawv tsis suav nrog hauv tsab xov xwm Creative Commons daim ntawv tso cai thiab koj qhov kev npaj siv tsis raug tso cai los ntawm txoj cai lij choj lossis tshaj qhov kev tso cai siv, koj yuav tsum tau txais kev tso cai ncaj qha los ntawm tus tuav ntaub ntawv.

cistanche flaccid

Cov ntaub ntawv

1. Egger G, et al. Epigenetics hauv tib neeg kab mob thiab kev cia siab rau kev kho mob epigenetic. Xwm. 2004; 429 (6990): 457–63.

2. Feil R, Fraga MF. Epigenetics thiab ib puag ncig: tawmqauv thiab cuam tshuam.

3. Nat Rev Genet. 2012; 13(2:97–109). Marsit CJ. Kev cuam tshuam ntawm ib puag ncig raug rau tib neeg kev tswj hwm epigenetic. J Exp Biol. 2015; 218(Pt 1): 71–9.

4. Li H., et al. Histone deacetylases 1 thiab 2 tswj cov kev pab cuam transcriptional ntawm nephron progenitors thiab raum vesicles.

5. Schedl A. Lub raum abnormalities thiab lawv cov keeb kwm kev loj hlob.

6. Nat Rev Genet. 2007; 8(10): 791–802. Aguilera O, et al. Epigenetics thiab ib puag ncig: kev sib raug zoo. J Appl Physiol (1985). 2010; 109(1): 243–51.

7. Beckerman P, Ko YA, Susztak K. Epigenetics: ib txoj hauv kev tshiab los saib cov kab mob raum. Nephrol Dial Hloov. 2014; 29(10): 1821–7.

8. Wanner N, Bechtel-Walz W. Epigenetics ntawm kab mob raum. Cell Tissue Res. 2017; 369(1):75–92.

9. El-Dahr SS, Saifudeen Z. Epigenetic kev cai ntawm lub raum kev loj hlob-menu. Semin Cell Dev Biol. 2019;

10. Berdasco M, Esteller M. Clinical epigenetics: txeeb lub cib fim rau kev txhais lus. Nat Rev Genet. 2019; 20(2):109–27.

11. Timmermann S, et al. Histone acetylation thiab kab mob. Cell Mol Lub Neej Sci CMLS. 2001; 58(5–6): 728–36.

12. Haberland M, Montgomery RL, Olson EN. Muaj ntau lub luag haujlwm ntawm histone deacetylases hauv kev loj hlob thiab kev noj qab haus huv: cuam tshuam rau kab mob thiab kev kho mob. Nat Rev Genet. 2009; 10(1:32–42).

13. Seto E, Yoshida M. Erasers ntawm histone acetylation: lub histone deacetylase enzymes. Cold Spring Harbor Perspect Biol. 2014;6(4):a018713.

14. Kelly RD, Cowley SM. Lub luag haujlwm physiological ntawm histone deacetylase (HDAC) 1 thiab 2: complex co-stars nrog ntau yam ua. Biochem Soc Trans. 2013; 41(3): 741–9.

15. Vermeulen M, et al. Nyob rau hauv vitro lub hom phiaj qhia txog qhov tseem ceeb ntawm lub cev histone tus Tsov tus tw ntawm Sin3 / histone deacetylase thiab N-CoR / SMRT corepressor complexes. Mol Cell Bio. 2004; 24(6): 2364–72.

16. Zhang X, et al. Ua kom muaj kev loj hlob-qhov sib txawv ntawm 11 noob los ntawm histone deacetylase (HDAC) inhibitor trichostatin A thiab kev tsim txom los ntawm HDAC3. Mol Cell Bio. 2004; 24(12): 5106–18.

17. Hayakawa T, Nakayama J. Physiological luag hauj lwm ntawm chav kawm I HDAC complex thiab histone demethylase. J Biomed Biotechnol. 2011; 2011: 129383.

18. Pfum MK, et al. Histone deacetylase 1 phosphorylation txhawb kev ua haujlwm enzymatic thiab txoj kev tsim. J Biol Chem. 2001; 276(50): 47733–41.

19. Tsai SC, Seto E. Regulation of histone deacetylase 2 by protein kinase CK2. J Biol Chem. 2002; 277(35):31826–33.

20. Galasinski SC, et al. Phosphatase inhibition ua rau histone deacetylases 1 thiab 2 phosphorylation thiab cuam tshuam ntawm corepressor kev sib cuam tshuam. J Biol Chem. 2002; 277(22): 19618–26.

21. Yoon S, et al. PP2A tsis zoo tswj cov lus teb hypertrophic los ntawm dephosphorylating HDAC2 S394 hauv plawv. Exp Mol Med. Xyoo 2018; 50(7): 83.

22. Montgomery RL, et al. Histone deacetylases 1 thiab 2 redundantly tswj lub plawv morphogenesis, kev loj hlob, thiab contractility. Genes Dev. 2007; 21(14): 1790–802.

23. Chen S., et al. Histone deacetylase (HDAC) kev ua haujlwm yog qhov tseem ceeb rau embryonic lub raum noob qhia, kev loj hlob, thiab kev sib txawv. J Biol Chem. 2011; 286(37):32775–89.

24. Hilliard SA, El-Dahr SS. Epigenetics ntawm lub raum kev loj hlob thiab kab mob. Yale J Biol Med. 2016; 89(4): 565–73.

25. Nie L, Young L, Zhang B, Zhao J. Daim ntawv thov ntawm histone deacetylase inhibitors nyob rau hauv lub raum interstitial fibrosis. Lub raum Dis. 2020; 6:226–35.

26. Brunmeir R, Lagger S, Seiser C. Histone deacetylase HDAC1/ HDAC2- tswj embryonic txoj kev loj hlob thiab kev sib txawv ntawm tes. Int J Dev Biol. 2009; 53(2–3): 275–89.

27. Chen S., et al. Histone deacetylase 1 thiab 2 tswj Wnt thiab p53 txoj hauv kev hauv ureteric bud epithelium. Kev loj hlob. 2015; 142(6): 1180–92.

28. El-Dahr S, Hilliard S, Saifudeen Z. Kev cai ntawm lub raum kev loj hlob los ntawm Mdm2/Mdm4-p53 axis. J Mol Cell Biol. 2017; 9(1):26–33.

29. Dressler GR. Ua ntej ntawm lub raum thaum ntxov specification, kev loj hlob, thiab qauv. Kev loj hlob. 2009; 136(23):3863–74.

30. Kobayashi A, et al. Rau 2 txhais thiab tswj hwm tus kheej muaj peev xwm rov ua dua tshiab nephron progenitor cov pej xeem thoob plaws hauv lub raum mammalian kev loj hlob. Cell Stem Cell. 2008; 3(2): 169–81.

31. Little MH, McMahon AP. Kev loj hlob ntawm lub raum Mammalian: cov hauv paus ntsiab lus, kev vam meej, thiab kev kwv yees. Txias Spring Harb Perspect Biol. 2012.

32. Wang L, et al. ASEB: lub web server rau KAT tshwj xeeb acetylation site twv ua ntej. Nucleic Acids Res. 2012; 40 (web server qhov teeb meem): W376–9.

33. Brodbeck S, Besenbeck B, Englert C. Qhov kev hloov pauv ntawm Six2 ua rau kev nthuav qhia ntawm Gdnf noob thiab nws tus kheej txhawb nqa. Mech Dev. 2004; 121(10):1211–22.

34. Hilliard S, et al. Txhais cov dynamic chromatin toj roob hauv pes ntawm nas nephron progenitors. Biol Qhib. 2019.

35. Kobayashi A, et al. Kev txheeb xyuas ntawm ntau tus kheej-renewing stromal progenitor pejxeem thaum lub sij hawm mammalian raum organogenesis. Stem Cell Rep. 2014; 3(4): 650–62.

36. Humphreys BD, et al. Txoj hmoo tracing qhia lub pericyte thiab tsis yog epithelial keeb kwm ntawm myofibroblasts nyob rau hauv lub raum fibrosis. Yog J Pathol. 2010; 176(1:85–97).

37. Ohmori T, et al. Sall1 nyob rau hauv lub raum stromal progenitors non-cell autonomously txwv qhov kev nthuav dav ntawm nephron progenitors. Sci Rep. 2015; 5:15676.

38. Hum S, et al. Ablation ntawm lub raum stroma tiv thaiv nws lub luag haujlwm tseem ceeb hauv nephron progenitor thiab vasculature patterning. PLOS IB. 2014; 9(2):e88400.

39. Liu N, Zhuang S. Kev kho mob raum kab mob nrog nws cov suab nrov deacetylase inhibitors. Pem hauv ntej Physiol. Xyoo 2015; 6:121.

40. Cianciolo Cosentino C, et al. Histone deacetylase inhibitor txhim kho kev rov zoo tom qab AKI. J Am Soc Nephrol JASN. 2013; 24(6):943–53.

41. Pang M, et al. Inhibition ntawm histone deacetylase kev ua si attenuates lub raum fibroblast activation thiab interstitial fibrosis hauv obstructive nephropathy. Am J Physiol Raum Physiol. 2009; 297(4): F996–1005.

42. Pang M, et al. Histone deacetylase 1/2 kho qhov kev loj hlob ntawm lub raum interstitial fibroblasts thiab kev qhia ntawm cell voj voog proteins. J Cell Biochem. 2011; 112(8): 2138–48.

43. Imai N, et al. Inhibition ntawm histone deacetylase activates sab pej xeem hlwb nyob rau hauv lub raum thiab ib nrab reverses mob raum mob. Stem Cells. 2007; 25(10): 2469–75.

44. Manson SR, et al. HDAC-dependent transcriptional repression ntawm Bmp-7 potentiates TGF-beta-mediated raum fibrosis hauv obstructive uropathy. J Urol. 2014; 191(1): 242–52.

45. Li N., et al. Thaiv chav kawm I histone deacetylase ameliorates lub raum fibrosis thiab inhibits lub raum fibroblast ua kom dhau los ntawm kev hloov pauv TGF-beta thiab EGFR signaling. PLOS IB. 2013; 8(1):e54001.

46. Yang M., et al. Inhibition ntawm chav kawm I HDACs attenuates raum interstitial fibrosis hauv murine qauv. Pharmacol Res. 2019; 142: 192–204.

47. Hadden MJ, Advani A. Histone deacetylase inhibitors thiab mob raum mob ntshav qab zib. Int J Mol Sci. 2018.

48. Gilbert RE, et al. Histone deacetylase inhibition attenuates mob ntshav qab zib-mob raum loj hlob: lub luag haujlwm muaj peev xwm rau kev hloov pauv ntawm epidermal loj hlob receptor. Raum Int. 2011; 79(12): 1312–21.

49. Advani A, et al. Lub sij hawm ntev kev tswj hwm ntawm histone deacetylase inhibitor vorinostat attenuates lub raum raug mob hauv kev sim ntshav qab zib los ntawm endothelial nitric oxide synthase-dependent mechanism. Yog J Pathol. 2011; 178(5): 2205–14.

50. Noh H, et al. Histone deacetylase-2 yog tus tswj xyuas qhov tseem ceeb ntawm ntshav qab zib thiab hloov pauv kev loj hlob-beta1- ua rau lub raum raug mob. Am J Physiol Raum Physiol. 2009; 297(3): F729–39.

51. Xu Z, et al. EGFR inhibition attenuates ntshav qab zib nephropathy los ntawm kev txo qis ROS thiab endoplasmic reticulum kev nyuaj siab. Onco phiaj. 2017; 8(20):32655–67.

52. Inoue K, et al. Podocyte histone deacetylase kev ua haujlwm tswj murine thiab tib neeg cov kab mob glomerular. J Clin Investig. 2019; 129(3): 1295–313.

53. Jacobsohn KM, Wood CG. Adjuvant therapy rau lub raum cell carcinoma. Semin Oncol. 2006; 33(5):576–82.

54. Fritzsche FR, et al. Chav kawm, I histone deacetylases 1, 2, thiab 3 tau qhia ntau heev hauv lub raum cell cancer. BMC Cancer. Xyoo 2008; 8:381.

55. Kiweler N, et al. Cov histone deacetylases HDAC1 thiab HDAC2 yuav tsum muaj rau kev loj hlob thiab ciaj sia ntawm lub raum carcinoma hlwb. Arch Toxicol. 2018; 92(7):2227–43.

56. Ramakrishnan S, et al. HDAC 1 thiab 6 modulate cell invasion thiab migration nyob rau hauv ntshiab cell cell carcinoma. BMC Cancer. Xyoo 2016; 16:617.

57. Marks PA. Histone deacetylase inhibitors: tshuaj genetics mus kom ze rau kev nkag siab txog kev ua haujlwm ntawm tes. Biochem Biophys Acta. 2010; 1799(10–12): 717–25.

58. Chun P. Kho cov teebmeem ntawm histone deacetylase inhibitors ntawm cov kab mob raum. Arch Pharmacy Res. 2018; 41(2): 162–83.

59. Jones J, et al. Lub histone deacetylase inhibitor valproic acid hloov cov khoom loj hlob ntawm lub raum cell carcinoma hauv vitro thiab hauv vivo. J Cell Mol Med. 2009; 13(8B): 2376–85.

60. Cha TL, et al. Dual degradation ntawm aurora A thiab B kinases los ntawm histone deacetylase inhibitor LBH589 induces G2-M ntes thiab apoptosis ntawm lub raum mob qog noj ntshav. Clin Cancer Res. 2009; 15(3): 840–50.

61. Kwon HK, et al. Ib qho tshiab gamma-lactam-based histone deacetylase inhibitor muaj zog inhibits kev loj hlob ntawm tib neeg lub mis thiab lub raum mob qog noj ntshav. Biol Pharm Bull. 2009; 32(10): 1723–7.

62. Suraweera A, O'Byrne KJ, Richard DJ. Kev sib xyaw ua ke nrog histone deacetylase inhibitors (HDACi) rau kev kho mob qog noj ntshav: ua tiav qhov kev kho mob tag nrho ntawm HDACi. Pem hauv ntej Oncology. Xyoo 2018; 8:92.

63. Juengel E, et al. Acetylation ntawm histone H3 tiv thaiv kev txhim kho tiv thaiv los ntawm kev mob ntev mTOR inhibition hauv lub raum cell carcinoma cells. Cancer Lett. 2012; 324(1): 83–90.

64. Pili R, et al. Immunomodulation los ntawm entinostat nyob rau hauv lub raum cell carcinoma cov neeg mob tau txais high-dose interleukin 2: ib tug multicenter, ib leeg-caj npab, theem I/II mus sib hais (NCI-CTEP # 7870). Clin Cancer Res. 2017a; 23(23): 7199–208.

65. Pili R, et al. Kev sib xyaw ua ke ntawm histone deacetylase inhibitor vorinostat nrog bevacizumab hauv cov neeg mob uas muaj lub raum tsis zoo ntawm lub raum cell carcinoma: multicentre, ib leeg-caj npab theem I / II kev sim tshuaj. Br J Cancer. 2017b; 116(7):874–83.